Cory Kasimov

The FDA AdCom meeting had the panel voting 12-1 in favor of waiting for TIGER-3 data for roci in T790M+ lung cancer. JPMorgan’s Cory Kasimov downgraded the rating for Clovis Oncology Inc (NASDAQ: CLVS) from Overweight to Neutral, while slashing the price target from $42 to $15....

Puma Biotechnology Inc (NYSE: PBYI) shares are down more than 26 percent on Tuesday and 29 percent since Monday's open. The stock's plunge comes on the back of news that the biotechnology company has plans to delay its NDA (New Drug Application) filing after meeting with the FDA (U.S. Food and Drug...

Shares of Celgene Corporation (NASDAQ: CELG) have declined 8.35 percent over the past month, touching a low of $104.52 on September 28. JP Morgan’s Cory Kasimov has upgraded Celgene from Neutral to Overweight, with a price target of $152. Kasimov believes that the stock’s...

Shares of bluebird bio Inc (NASDAQ: BLUE) were rallying in Monday’s pre-market session, spiking over 5 percent before falling back down to the $180 range by mid-day. The catalyst for the spike was due to encouraging results of an experimental gene therapy product called LentiGlobin...

JP Morgan downgraded MannKind Corporation (NASDAQ: MNKD) Monday from Neutral to Underweight following Friday’s earnings release. Analysts led by Cory Kasimov noted that sales of Afrezza had been slow with Q1 sales coming in at approximately $1.1 million. “What’s more...

Keryx Biopharmaceuticals (NASDAQ: KERX) reported first quarter 2015 earnings on May 4. All eyes were on Auryxia, Keryx’s lead product for patients with chronic kidney disease on dialysis. Keryx posted total revenue of $1.175 million, including 1,218 prescriptions filled for Auryxia in the...

Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 results on Wednesday and posted adjusted of EPS $0.96, above estimates of $0.76, on revenues of $290.2 million. The company also reaffirmed its fiscal 2015 outlook. JP Morgan analyst Cory Kasimov felt that the company’s long-term future...

Want an edge on biotech stocks? Try this. Learn more about investing in the biotech sector with real-time trading picks from experts like the Biotech Trader. In a report published Wednesday morning, J.P. Morgan analyst Cory Kasimov reiterated an Overweight rating on Gilead Sciences, Inc.(...

Gilead Sciences, Inc. (NASDAQ: GILD) shares spiked over the $104 level Friday morning following a Barron’s blog post. The blog post asked if it is time for investors to look beyond hepatitis-C drugs. JP Morgan’s Cory Kasimov was quoted as noting that there is “intense focus on...

JP Morgan initiated coverage on Novavax, Inc. (NASDAQ: NVAX) with an Overweight rating and $7 price target. Analyst Cory Kasimov noted that he is "impressed by the potential of the company’s proprietary recombinant nanoparticle vaccine technology" and he believed that...

In a report published Tuesday, J.P. Morgan analyst Cory Kasimov reiterated an Overweight rating and $22.00 price target on Sangamo Biosciences, Inc. (NASDAQ: SGMO). In the report, J.P. Morgan noted, “SGMO today provided an update on the ongoing Phase 1/2 trials of SB-728-T in HIV infected patients...

In a report published Friday, J.P. Morgan analyst Cory Kasimov initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with an Overweight rating and $22.00 price target. In the report, J.P. Morgan noted, “We are initiating coverage of SGMO with an OW rating and YE15 price target of $22 based on...

JP Morgan analyst Cory Kasimov downgrades Vivus (NASDAQ: VVUS) Tuesday morning, lowering rating from Overweight to Neutral, while moving their price target from $15 to $8. The report notes that Qsymia has been on the market for a year and a half without any catalyst or signs of progression, "With...